secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001447362-25-000012
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences expects 2024 revenue at least $330M (≥50% growth); Medicare non-covers DecisionDx-SCC
--------------------------------------------------------------------------------

- Full-year 2024 revenue expected to meet or exceed top of guidance range $320-330M, at least 50% growth over 2023.
- Delivered 96,071 total test reports in 2024, up 36% YoY; TissueCypher Barrett's Esophagus test grew 130%.
- Year-end 2024 cash, cash equivalents and marketable securities approximately $293M.
- Medicare contractor Novitas finalized non-coverage for DecisionDx-SCC test on January 9, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736225000012/0001447362-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736225000012/cstl-20250112.htm
  HTML page:      https://secwatch.observer/filing/0001447362-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer